Compare AX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | ELVN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.2B |
| IPO Year | 2004 | 2020 |
| Metric | AX | ELVN |
|---|---|---|
| Price | $91.87 | $44.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $117.71 | $74.42 |
| AVG Volume (30 Days) | 332.7K | ★ 1.6M |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.13 | 3.17 |
| EPS | ★ 2.25 | N/A |
| Revenue | ★ $81,254,000.00 | N/A |
| Revenue This Year | $11.96 | N/A |
| Revenue Next Year | $9.49 | N/A |
| P/E Ratio | $42.03 | ★ N/A |
| Revenue Growth | ★ 23.51 | N/A |
| 52 Week Low | $74.89 | $14.79 |
| 52 Week High | $105.74 | $62.32 |
| Indicator | AX | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 61.80 |
| Support Level | $94.35 | $44.18 |
| Resistance Level | $100.94 | $47.88 |
| Average True Range (ATR) | 2.34 | 1.84 |
| MACD | 0.60 | 1.04 |
| Stochastic Oscillator | 68.62 | 99.42 |
Axos Financial Inc is a technology-driven, diversified financial services company. Its client-centric, technology-enabled services model provides secure and scalable banking, clearing and custody, and investment advisory solutions to retail and business customers. The Bank provides consumer and commercial banking products and services through its digital online and mobile banking platforms, low-cost distribution channels and affinity partners. It offers deposit and lending products to customers nationwide including consumer and business checking, savings, etc. Its segments are Banking Business Segment and the Securities Business Segment. Majority of income comes from Banking Business Segment- It distribute its loan products through its retail, correspondent and wholesale channels.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.